Methods | This study was based in Kaiser Permanente Southern California using data from June 9, 2016, through June 30, 2017, with follow-up through August 20, 2017. An executive EOLOA task force was formed 7 months prior to the EOLOA taking effect with representatives from bioethics, operations, quality, psychiatry, pharmacy, education, nursing, legal, and palliative care to ensure appropriate policy and structures were in place. Key implementation steps included the following: physicians were surveyed about their willingness to participate after viewing an educational video; staff were trained regarding how to manage EOLOA requests; additional training was provided for volunteer physicians; volunteer pharmacists were identified to dispense and provide education on proper use of the medications; and training was provided for The primary responsibilities of the EOLOA coordinators were to provide assistance with navigation to patients, perform psychosocial assessments, serve as a resource for health care professionals involved in the care of these patients, ensure the integrity of informed consent and compliance with the legal requirements, and be available for staff debriefing after patient deaths. Data for this study were obtained from electronic medical records, logs maintained by the EOLOA coordinators, and standard state reporting forms. The study was approved by the Kaiser Permanente Southern California institutional review board and informed consent was waived owing to the retrospective nature of the study. Descriptive statistics were performed with SAS statistical software (version 9.3, SAS Institute, Inc).
Results | A total of 379 patients initiated an inquiry from June 9, 2016, through June 30, 2017 (Figure) . Of these, 79 (21%) patients died or were too ill to proceed, 61 (16%) were ineligible, and 176 (46%) who were deemed eligible proceeded with their first spoken request to an attending physician. Many of the withdrawals at each step of the EOLOA process were owing to death or patients being too ill. Sixty-eight (74%) of the 92 patients who received the EOLOA drugs ingested them and died within a median of 9 days after the prescription was written. The sociodemographic, clinical, and end-of-life care characteristics of patients who completed the first oral request, proceeded to receive a prescription for the aid-in-dying drugs, and ingested the drugs were for the most part similar (Table) . Most patients who initiated EOLOA had cancer (74%) and received care primarily from specialists in the previous 12 months. Ninety-six (55%) patients had an activities of daily living impairment and were on palliative care or hospice at the time of their inquiry. The 2 most common reasons patients cited for pursuing EOLOA were that they did not want to suffer and that they were no longer able to participate in activities that made life enjoyable.
Discussion | To our knowledge, this is the first detailed report describing the outcome and characteristics of all individuals who initiated the EOLOA process from a large health care system in California. The characteristics of this sample were similar to a recent report 2 with the exception that a higher percentage of these patients proceeded with ingesting the aidin-dying drugs (75% vs 59%); this may be owing to the longer follow-up time. Similar to Oregon's experience, 4 patients' endof-life concerns appear difficult to palliate with the most common cited reasons for pursuing EOLOA being existential suffering, inability to enjoy life, and loss of autonomy. Implementation), Eduard Gelman (SCPMG Consulting and Implementation), Tracey Bush, LCSW (Practice Leader for EOLOA) and the EOLOA social work coordinators for their helpful comments on drafts of the manuscript. We also thank Lindsay-Joe Lyons, LVN, and Gordon Tam, MD, Kaiser Permanente Southern California, for their assistance with the medical chart reviews. They were not compensated. We also thank the patients of Kaiser Permanente and their partnership with us to improve their health.
